Immunis, Inc.
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Regenerative Medicine
Immunis is a clinical-stage biotech developing a first-in-class stem cell-derived secretome product targeting the underlying factors of aging biology that drive immune-mediated muscle and metabolic disease. IMM01-STEM is an investigational biologic comprised of regenerative factors that impact multiple signaling pathways. Immunis completed two exploratory Phase 2a trials which showed that IMM01-STEM provided a clinically meaningful improvement in mobility and metabolic function in two sarcopenic populations with obesity and knee osteoarthritis, respectively. Published preclinical studies in aged and obese mice treated with IMM01-STEM showed higher muscle quality, greater muscle function, increased energy expenditure, enhanced metabolism, improved body composition, and reduced liver fat and fibrosis. Immunis is dedicated to maximizing healthspan and to minimizing disease through the advancement of transformative, multi-active medicine.
Company HQ City:
Irvine
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
IMM01-STEM, a stem cell-derived multi-active biologic
CEO
Dr. Hans Keirstead, Chairman
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1, IMM01-STEM
When you expect your next catalyst update?
Confirmatory Phase 2b clinical trials to be initiated by Mar 2028
What is your next catalyst (value inflection) update?
Currently achieved in Q1 2026 exploratory topline Phase 2a clinical data supporting gait speed benefits, triggering a Series B fundraising round
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}